Brainsway (NASDAQ:BWAY) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Key Points

• Brainsway (NASDAQ:BWAY) reported a quarterly earnings per share (EPS) of $0.10, exceeding analysts' expectations of $0.07 by $0.03.
• The company's revenue for the quarter was $12.63 million, surpassing analyst estimates of $12.34 million.
• Analysts have varied views on BWAY stock, with HC Wainwright raising their price target to $17.00, while Wall Street Zen has downgraded it from a "buy" to a "hold" rating.

Brainsway (NASDAQ:BWAY - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of $0.07 by $0.03, Zacks reports. Brainsway had a return on equity of 8.97% and a net margin of 11.60%.The company had revenue of $12.63 million during the quarter, compared to analysts' expectations of $12.34 million. Brainsway updated its FY 2025 guidance to EPS.

Brainsway Trading Down 2.6%

NASDAQ:BWAY traded down $0.38 during trading hours on Tuesday, hitting $14.47. The company had a trading volume of 87,142 shares, compared to its average volume of 56,977. The company has a 50-day moving average of $12.21 and a 200 day moving average of $10.59. The company has a market cap of $273.48 million, a P/E ratio of 55.66 and a beta of 1.42. Brainsway has a 1 year low of $7.06 and a 1 year high of $15.00.

Analyst Ratings Changes

Several analysts have commented on the stock. Northland Securities lifted their price objective on shares of Brainsway from $15.00 to $19.00 and gave the company an "outperform" rating in a research note on Thursday, August 14th. HC Wainwright boosted their price target on Brainsway from $16.00 to $17.00 and gave the company a "buy" rating in a report on Thursday, August 14th. Finally, Wall Street Zen raised shares of Brainsway from a "hold" rating to a "buy" rating in a research note on Sunday. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $18.00.

Institutional Trading of Brainsway

A hedge fund recently raised its stake in Brainsway stock. NewEdge Advisors LLC increased its holdings in Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY - Free Report) by 34.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 26,665 shares of the company's stock after acquiring an additional 6,837 shares during the period. NewEdge Advisors LLC owned approximately 0.14% of Brainsway worth $351,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 30.11% of the company's stock.

About Brainsway

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.